# CRISPR-Based Therapy for Hereditary Angioedema.

- **DOI:** [10.1056/nejmoa2405734](https://doi.org/10.1056/nejmoa2405734)
- **Rating:** Sound (3.6 out of 5)
- **Verdict:** Single-dose NTLA-2002 delivers controlled clinical and pharmacodynamic signals in hereditary angioedema, but the small phase 2 comparison leaves efficacy uncertain.
- **Framework version:** v5.10
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-11-03
- **Evaluation page:** https://www.nabu.science/paper/10.1056%2Fnejmoa2405734

## Key claims

1. NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema.
   - Support: Tentative
   - Type: Primary finding
   - Basis: small exploratory randomized comparison with a 16-week primary window and clinical effect intervals including no benefit
   - Location: Abstract — Conclusions
2. The mean percent change in total plasma kallikrein protein levels from baseline to week 16 was -55% with 25 mg and -86% with 50 mg; levels remained unchanged with placebo.
   - Support: Well-supported
   - Type: Secondary
   - Basis: direct pharmacodynamic measurements show consistent dose-dependent lowering relative to unchanged placebo levels
   - Location: Abstract — Results; Fig. 2
3. Among patients who received NTLA-2002, 4 of the 10 patients who received 25 mg (40%) and 8 of the 11 who received 50 mg (73%) were attack-free with no additional treatment during the period from week 1 through week 16.
   - Support: Supported
   - Type: Secondary
   - Basis: directly reported descriptive counts in small treatment groups over a short primary observation period
   - Location: Abstract — Results; Results — Efficacy
4. 12 of 15 patients (80%) who received 50 mg of NTLA-2002 have remained attack-free for periods ranging from 12 weeks (phase 2) to approximately 19 months (phase 1)
   - Support: Tentative
   - Type: Secondary
   - Basis: pooled small cohorts with heterogeneous follow-up and an uncontrolled phase 1 extension
   - Location: Discussion — Phase 1 update
5. No new safety concerns arose, and no serious adverse events occurred in patients who received NTLA-2002.
   - Support: Supported
   - Type: Secondary
   - Basis: observed event reporting in a small treated population with insufficient exposure to exclude rare or delayed harms
   - Location: Discussion — final paragraph; Table 3

## Strengths

- **Randomized evidence advances single-dose editing development** The placebo-controlled phase 2 comparison extends prior dose-escalation findings with clinical attack-rate estimates and attack-free proportions in patients.
  - Dimension: contribution
  - Location: Introduction — prior phase 1 study; Methods — Trial Design; Results — Efficacy
- **Blinded analysis and systematic harms reporting** All randomized patients enter the efficacy analysis, the primary model adjusts for baseline attack rate, and adverse events are graded and reported with denominators.
  - Dimension: methodological rigour
  - Location: Methods — Clinical Assessment and Statistical Analysis; Table 3
- **Clinical need and development pathway align** The single-infusion strategy addresses the burden of repeated lifelong prophylaxis, and the conclusion identifies a larger phase 3 trial as the next step.
  - Dimension: application pathway
  - Location: Introduction — prophylaxis burden; Discussion — final paragraph

## Limitations

- **Small controlled comparison leaves efficacy imprecise** The trial randomized 27 patients, including six placebo recipients, without a formal power calculation. Primary percentage-difference intervals span -95 to 27 and -95 to 15, including no benefit.
  - Dimension: methodological rigour
  - Location: Methods — Statistical Analysis; Table 2
- **Headline efficacy wording exceeds comparative certainty** The abstract states that NTLA-2002 reduced attacks, while the primary placebo comparisons remain inconclusive. The functional-cure framing is prospective rather than demonstrated.
  - Dimension: reporting
  - Location: Abstract — Conclusions; Table 2; Discussion — final paragraph
- **Permanent editing needs longer safety context** The 16-week controlled window and limited treated population cannot resolve rare or delayed harms. Discussion gives limited attention to editing-specific long-term risks.
  - Dimension: positioning
  - Location: Methods — primary observation period; Table 3; Discussion — safety and limitations

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted. One reported value does not reconcile, but the key claims do not rest on it.
  - Minor reporting notes (1):
    - Descriptive: "We planned to enroll a total of up to 25 patients (20 patients in the NTLA-2002 groups and 5 in the placebo group)" (Methods — Statistical Analysis) vs "27 underwent randomization: 10 patients were assigned to receive 25 mg of NTLA-2002, 11 were assigned to receive 50 mg, and 6 were assigned to receive placebo." (Results — Patients). Compare planned enrollment of up to 25 with actual enrollment of 10 + 11 + 6 = 27, an unexplained excess of two participants rather than an arithmetic contradiction. → Effect on result unclear
- **Reporting and transparency:** Clean. Ethics approval, informed consent, trial registration, funding, and sponsor involvement are disclosed. Referenced oversight and data-sharing materials were not independently verified.
  - Conflict of interest: declared · Ethics approval: declared · Preregistration: declared · Data availability: declared
- **Reference integrity:** Clean. 21 of 21 checkable references verified
  - 24 references in manuscript
  - 3 have no canonical index record — counted, but not index-checkable
  - 2 references confirmed by manual review
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-11-03